<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">TCM</journal-id><journal-title-group><journal-title>Traditional Chinese Medicine</journal-title></journal-title-group><issn pub-type="epub">2166-6067</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/TCM.2021.103048</article-id><article-id pub-id-type="publisher-id">TCM-42506</article-id><article-categories><subj-group subj-group-type="heading"><subject>TCM20210300000_13488480.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  探索“脾主为卫”环节对糖脂代谢稳态的调节机制
  Explore Regulation Mechanism of “The Spleen for Defend” on Homeostasis of Glucose and Fat Metabolism
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>李</surname><given-names>莉</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>王</surname><given-names>涛</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff3"><addr-line>天津中医药大学，中医药研究院，天津</addr-line></aff><aff id="aff2"><addr-line>广西中医药大学，药学院，广西 南宁</addr-line></aff><aff id="aff1"><addr-line>null</addr-line></aff><pub-date pub-type="epub"><day>07</day><month>04</month><year>2021</year></pub-date><volume>10</volume><issue>03</issue><fpage>343</fpage><lpage>251</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  目的：运用益气活血法探索“脾主为卫”环节调节糖脂代谢紊乱的潜在分子机制。方法：采用Western Blot法研究金芪降糖方对KKAy小鼠肝脏和肌肉中PI3K/AKT信号通路的影响；观察金芪降糖方在体外对HepG2细胞TG蓄积的作用和机制。结果表明：金芪降糖方明显上调KKAy小鼠骨骼肌内PI3K、p-PI3K、AKT、p-AKT蛋白的表达；金芪降糖方及其组分均具有降低HepG2细胞TG蓄积的作用，且具有明显的量效关系；应用分别加入抑制剂或激动剂的方法后，其抑制作用依然存在，但抑制作用明显降低，表明金芪降糖方抑制TG蓄积可能与激活PI3K/AKT和AMPK信号通路有关。结论：“脾主为卫”环节通过促进机体胰岛微循环从而发挥其改善糖脂代谢紊乱的作用，其机制可能与同时干预多条通路以调节疾病状态下失衡的代谢网络相关。
  Objective: To analyze the molecular biological mechanism of “The Spleen for Defend” regulating glucose and lipid metabolism disorder. Method: The effects of “Jinqi jiangtang” formula on the PI3K/AKT pathway in the liver and muscle of KKAy mice were studied by Western Blot. HepG2 cells were induced by sodium oleate to build lipid accumulation model. Inhibitors such as Com-pound C (AMPK inhibitor), STO-609 (CaMKK inhibitor), Oxtromorine (acetylcholine receptor inhibitors), Cytochalasin B (GLUT4 inhibitors), and agonist IGF-1 (PI3K agonist) were used to explore possible mechanism of lipid regulation. It is suggested that possible mechanism on TG accumulation of “Jinqi jiangtang” formula could inhibit TG accumulation through activating AMPK and PI3K/AKT signaling pathway. Conclusion: The effects of “The Spleen for Defend” on the improvement of the disturbance in the lipid and glucose metabolism may be achieved by promoting islet microcirculation, and its mechanism may be related to intervention of multiple pathways to regulate the unbalanced metabolic network in the state of disease.
 
</p></abstract><kwd-group><kwd>脾主为卫，益气活血法，金芪降糖方，糖脂代谢病, The Spleen for Defend</kwd><kwd> Qi-Invigorating and Blood-Activation Therapy</kwd><kwd> “Jinqi jiangtang” Formula</kwd><kwd> Glycolipid Metabolic Disease</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>摘要</title><p>目的：运用益气活血法探索“脾主为卫”环节调节糖脂代谢紊乱的潜在分子机制。方法：采用Western Blot法研究金芪降糖方对KKA<sup>y</sup>小鼠肝脏和肌肉中PI3K/AKT信号通路的影响；观察金芪降糖方在体外对HepG2细胞TG蓄积的作用和机制。结果表明：金芪降糖方明显上调KKA<sup>y</sup>小鼠骨骼肌内PI3K、p-PI3K、AKT、p-AKT蛋白的表达；金芪降糖方及其组分均具有降低HepG2细胞TG蓄积的作用，且具有明显的量效关系；应用分别加入抑制剂或激动剂的方法后，其抑制作用依然存在，但抑制作用明显降低，表明金芪降糖方抑制TG蓄积可能与激活PI3K/AKT和AMPK信号通路有关。结论：“脾主为卫”环节通过促进机体胰岛微循环从而发挥其改善糖脂代谢紊乱的作用，其机制可能与同时干预多条通路以调节疾病状态下失衡的代谢网络相关。</p></sec><sec id="s2"><title>关键词</title><p>脾主为卫，益气活血法，金芪降糖方，糖脂代谢病</p></sec><sec id="s3"><title>Explore Regulation Mechanism of “The Spleen for Defend” on Homeostasis of Glucose and Fat Metabolism</title><p>Li Li<sup>1</sup>, Tao Wang<sup>2</sup></p><p><sup>1</sup>Faculty of Pharmacy, Guangxi University of Chinese Medicine, Nanning Guangxi</p><p><sup>2</sup>Institute of Traditional Chinese Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin</p><p><img src="//html.hanspub.org/file/9-2270666x4_hanspub.png" /></p><p>Received: Mar. 5<sup>th</sup>, 2021; accepted: May 17<sup>th</sup>, 2021; published: May 24<sup>th</sup>, 2021</p><p><img src="//html.hanspub.org/file/9-2270666x5_hanspub.png" /></p></sec><sec id="s4"><title>ABSTRACT</title><p>Objective: To analyze the molecular biological mechanism of “The Spleen for Defend” regulating glucose and lipid metabolism disorder. Method: The effects of “Jinqi jiangtang” formula on the PI3K/AKT pathway in the liver and muscle of KKA<sup>y</sup> mice were studied by Western Blot. HepG2 cells were induced by sodium oleate to build lipid accumulation model. Inhibitors such as Compound C (AMPK inhibitor), STO-609 (CaMKK inhibitor), Oxtromorine (acetylcholine receptor inhibitors), Cytochalasin B (GLUT4 inhibitors), and agonist IGF-1 (PI3K agonist) were used to explore possible mechanism of lipid regulation. It is suggested that possible mechanism on TG accumulation of “Jinqi jiangtang” formula could inhibit TG accumulation through activating AMPK and PI3K/AKT signaling pathway. Conclusion: The effects of “The Spleen for Defend” on the improvement of the disturbance in the lipid and glucose metabolism may be achieved by promoting islet microcirculation, and its mechanism may be related to intervention of multiple pathways to regulate the unbalanced metabolic network in the state of disease.</p><p>Keywords:The Spleen for Defend, Qi-Invigorating and Blood-Activation Therapy, “Jinqi jiangtang” Formula, Glycolipid Metabolic Disease</p><disp-formula id="hanspub.42506-formula31"><graphic xlink:href="//html.hanspub.org/file/9-2270666x6_hanspub.png"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2021 by author(s) and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY 4.0).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/9-2270666x7_hanspub.png" /> <img src="//html.hanspub.org/file/9-2270666x8_hanspub.png" /></p></sec><sec id="s5"><title>1. 引言</title><p>血脂异常是动脉粥样硬化、冠心病、脑卒中等心脑血管疾病的重要危险因素。成人血脂异常总体患病率高达40.40%，且常伴有糖代谢异常 [<xref ref-type="bibr" rid="hanspub.42506-ref1">1</xref>] [<xref ref-type="bibr" rid="hanspub.42506-ref2">2</xref>] [<xref ref-type="bibr" rid="hanspub.42506-ref3">3</xref>]。学术界将糖尿病、高脂血症、脂肪肝、动脉粥样硬化归为糖脂代谢病范畴 [<xref ref-type="bibr" rid="hanspub.42506-ref4">4</xref>]。中医学认为糖脂代谢病应归属于“脾主为卫”功能失常 [<xref ref-type="bibr" rid="hanspub.42506-ref5">5</xref>]，运化失司累及血脉，气虚血瘀既是病理因素也是病理产物 [<xref ref-type="bibr" rid="hanspub.42506-ref6">6</xref>]。然而，目前研究多集中在理论研究和临床观察上，其作用机制尚未完全阐释。基于前期研究发现，益气活血方药能够降低血脂和血糖浓度，减少甘油三脂和糖原在肝组织的蓄积，从而调节糖脂代谢 [<xref ref-type="bibr" rid="hanspub.42506-ref7">7</xref>]。该研究建立了津液代谢中“脾主为卫”过程与糖脂代谢之间的联系。本文将进一步从细胞分子水平探讨机体“脾主为卫”环节对糖脂代谢的调节机制。</p></sec><sec id="s6"><title>2. 实验材料与方法</title><sec id="s6_1"><title>2.1. 主要材料</title><p>液质联用仪，低温高速离心机，美国Beckman公司。多功能微孔板分析仪，美国Molecular Devices公司。基因扩增仪，美国Perkin Elmer仪器公司。实时荧光定量PCR仪，美国Applied Biosystems公司。甘油三酯(TG)试剂盒，中生北控生物科技股份有限公司。</p></sec><sec id="s6_2"><title>2.2. 实验方法</title><sec id="s6_2_1"><title>2.2.1. 金芪降糖方对KKA<sup>y</sup>小鼠肝脏和骨骼肌中糖脂代谢相关蛋白表达水平的影响</title><p>将C57BL/6J小鼠作为空白对照组， KKA<sup>y</sup>小鼠(北京华阜康生物科技股份有限公司)根据所测血糖值随机分为模型组、罗格列酮(市售，葛兰素史克(天津)有限公司，批号：09120151)组(10 mg/kg，5%的阿拉伯胶)、金芪降糖高剂量组(500 mg/kg，5%的阿拉伯胶)、金芪降糖低剂量组(250 mg/kg，5%的阿拉伯胶)。给药组给予相应剂量药物，空白组C57BL/6J小鼠和模型组KKA<sup>y</sup>小鼠灌胃等体积阿拉伯胶，灌胃体积为20 ml/kg。每日各组于16:00~17:00灌胃一次。末次给药前禁食12 h，过量麻醉处死动物，解剖，分别取肝脏、骨骼肌组织进行蛋白质的提取和定量。应用SDS-PAGE电泳方法(具体方法：配制10%分离胶和5%浓缩胶，样品首先在70 V恒定电压下电泳至溴酚蓝接近分离胶的顶端，然后在100 V的恒定电压下电泳至溴酚蓝刚出胶底部即可终止电泳，进行转膜，使用半干转仪17 V恒定电压下转膜45 min。将转移好的膜移至封闭液中，室温下摇动封闭3 h，加入一抗(1:800)，4℃孵育过夜。洗涤后加入二抗(1:10,000)，室温下摇动孵育2 h后进行显色反应。应用多功能成像分体系统结合Quantity one v 4.62软件进行扫描和拍照，分析目标条带的灰度值)，然后测定PI3K、p-PI3K、AKT、p-AKT、GYS、p-GYS、GLUT4、PPAR-γ蛋白的表达。</p></sec><sec id="s6_2_2"><title>2.2.2. 金芪降糖方对HepG2细胞脂质蓄积的影响</title><p>1) 细胞的培养</p><p>HepG2细胞株(购于中国医学科学院协和细胞库)。使用含10%胎牛血清、1%非必需氨基酸的MEM培养液，在37&#186;C，5% CO<sub>2</sub>的恒温培养箱中培养细胞，培养24 h后诱导分化，并采用MTT比色法(3-(4，5-二甲基噻唑-2)-2,5-二苯基四氮唑溴盐)计算细胞存活率。存活率% = A<sub>样品组</sub>/A<sub>对照组</sub> &#215; 100。</p><p>2) 金芪降糖方对HepG2细胞脂质蓄积的影响</p><p>金芪降糖全方及各组分提取物(天津中医药大学中医药研究院中药化学实验室)用DMSO配制为64 mg/ml，-20℃保存，供细胞加药使用，实验终浓度为10 μmol/L、1 μmol/L、0.1 μmol/L。</p><p>将HepG2细胞分为空白组、模型组(200 μmol/L油酸钠)、阳性药组(1 μmol/L Orli)、金芪降糖方及其组分高、低剂量组。制造TG蓄积模型。加药后作用48 h后，GPO-PAP法检测TG含量。</p><p>3) 金芪降糖方及其组分对HepG2细胞脂质蓄积作用机制的研究</p><p>将HepG2细胞分为空白组、模型组(200 &#181;M油酸钠)、阳性药组(1 μM Orli)、黄芪总皂苷组(10 &#181;g/ml AS)、黄芪总黄酮组(10 &#181;g/ml HT)、黄连总生物碱组(10 &#181;g/ml CA)、金芪降糖方全方组(10 &#181;g/ml JQ)、金银花总有机酸组(10 &#181;g/ml LA)以及相应抑制剂与激动剂处理组诱导分化细胞，制造TG蓄积模型。给药48 h后，GPO-PAP法检测TG含量。</p></sec></sec><sec id="s6_3"><title>2.3. 统计学处理</title><p>所有数据应用SPSS16.0统计软件进行分析。检测结果以均数&#177;标准差( x &#175; &#177; s )表示，采用单因素方差分析(One-way ANOVA)(Fisher检验)或者Wilcoxon秩和检验，符合正态性检验和方差齐性检验者使用F检验，多组间两两检验用LSD、图凯检验法(Tukey’s studentized range tests)或者Student-Newman-Keuls法。P &lt; 0.05表明具有统计学差异。</p></sec></sec><sec id="s7"><title>3. 实验结果</title><sec id="s7_1"><title>3.1. 金芪降糖方对KKA<sup>y</sup>小鼠肝脏和骨骼肌中糖脂代谢相关蛋白表达水平的影响</title><p>由表1和表2可知，肝脏和骨骼肉中的金芪高、低剂量组PI3K、p-PI3K、AKT、p-AKT蛋白表达量较模型组均升高，其中在骨骼肌中尤为明显(P &lt; 0.05)；各组蛋白Western表达条带如图1所示。</p></sec><sec id="s7_2"><title>3.2. 金芪降糖方复方及其各组分对诱导后HepG2细胞内TG含量的影响</title><sec id="s7_2_1"><title>3.2.1. 金芪降糖方及其组分对诱导后HepG2细胞存活率的影响</title><p>如表3所示，不同给药剂量下，金芪降糖方及其组分对HepG2细胞都不具有明显细胞毒作用。</p><p>图1. 金芪降糖方对KKAy小鼠糖脂代谢相关蛋白表达水平的影响</p><table-wrap id="table1" ><label><xref ref-type="table" rid="table1">Table 1</xref></label><caption><title> Grayscale analysis of Jinqi Jiangtang formula on liver protein expression in KKAy mic</title></caption><table><tbody><thead><tr><th align="center" valign="middle" ></th><th align="center" valign="middle" >PI3K/β-actin</th><th align="center" valign="middle" >p-PI3K/β-actin</th><th align="center" valign="middle" >AKT/β-actin</th><th align="center" valign="middle" >p-AKT/β-actin</th></tr></thead><tr><td align="center" valign="middle" >N</td><td align="center" valign="middle" >0.09 &#177; 0.01</td><td align="center" valign="middle" >0.14 &#177; 0.03</td><td align="center" valign="middle" >0.07 &#177; 0.09</td><td align="center" valign="middle" >0.15 &#177; 0.04</td></tr><tr><td align="center" valign="middle" >C</td><td align="center" valign="middle" >0.13 &#177; 0.03</td><td align="center" valign="middle" >0.19 &#177; 0.04</td><td align="center" valign="middle" >0.19 &#177; 0.08</td><td align="center" valign="middle" >0.41 &#177; 0.12</td></tr><tr><td align="center" valign="middle" >R</td><td align="center" valign="middle" >0.16 &#177; 0.02</td><td align="center" valign="middle" >0.22 &#177; 0.05</td><td align="center" valign="middle" >0.22 &#177; 0.07</td><td align="center" valign="middle" >0.54 &#177; 0.12</td></tr><tr><td align="center" valign="middle" >High</td><td align="center" valign="middle" >0.25 &#177; 0.06</td><td align="center" valign="middle" >0.34 &#177; 0.07</td><td align="center" valign="middle" >0.39 &#177; 0.11</td><td align="center" valign="middle" >0.69 &#177; 0.15</td></tr><tr><td align="center" valign="middle" >Low</td><td align="center" valign="middle" >0.17 &#177; 0.03</td><td align="center" valign="middle" >0.29 &#177; 0.05</td><td align="center" valign="middle" >0.33 &#177; 0.08</td><td align="center" valign="middle" >0.62 &#177; 0.14</td></tr></tbody></table></table-wrap><p>表1. 金芪降糖方对KKA<sup>y</sup>小鼠肝脏蛋白表达灰度分析(n = 7, x &#175; &#177; s )</p><p>注：N为空白组；C：模型对照组；R：罗格列酮治疗组(100 mg/kg/d)；High：金芪降糖方高剂量组(500 mg/kg/d)；Low：金芪降糖方低剂量组(250 mg/kg/d)。</p><table-wrap id="table2" ><label><xref ref-type="table" rid="table2">Table 2</xref></label><caption><title> Grayscale analysis of Jinqi Jiangtang formula on muscle protein expression in KKAy mic</title></caption><table><tbody><thead><tr><th align="center" valign="middle" ></th><th align="center" valign="middle" >PI3K/β-actin</th><th align="center" valign="middle" >p-PI3K/β-actin</th><th align="center" valign="middle" >AKT/β-actin</th><th align="center" valign="middle" >p-AKT/β-actin</th></tr></thead><tr><td align="center" valign="middle" >N</td><td align="center" valign="middle" >0.14 &#177; 0.01</td><td align="center" valign="middle" >0.13 &#177; 0.06</td><td align="center" valign="middle" >0.12 &#177; 0.03</td><td align="center" valign="middle" >0.12 &#177; 0.03</td></tr><tr><td align="center" valign="middle" >C</td><td align="center" valign="middle" >0.30 &#177; 0.11</td><td align="center" valign="middle" >0.31 &#177; 0.07</td><td align="center" valign="middle" >0.16 &#177; 0.03</td><td align="center" valign="middle" >0.17 &#177; 0.03</td></tr><tr><td align="center" valign="middle" >R</td><td align="center" valign="middle" >0.57 &#177; 0.14</td><td align="center" valign="middle" >0.56 &#177; 0.13</td><td align="center" valign="middle" >0.24 &#177; 0.04</td><td align="center" valign="middle" >0.30 &#177; 0.05</td></tr><tr><td align="center" valign="middle" >High</td><td align="center" valign="middle" >1.20 &#177; 0.32<sup>*</sup></td><td align="center" valign="middle" >1.06 &#177; 0.22<sup>**</sup></td><td align="center" valign="middle" >0.66 &#177; 0.11<sup>***</sup></td><td align="center" valign="middle" >0.89 &#177; 0.12<sup>***</sup></td></tr><tr><td align="center" valign="middle" >Low</td><td align="center" valign="middle" >0.89 &#177; 0.36<sup>*</sup></td><td align="center" valign="middle" >0.78 &#177; 0.21<sup>*</sup></td><td align="center" valign="middle" >0.48 &#177; 0.05<sup>**</sup></td><td align="center" valign="middle" >0.59 &#177; 0.07<sup>***</sup></td></tr></tbody></table></table-wrap><p>表2. 金芪降糖方对KKA<sup>y</sup>小鼠肌肉蛋白表达灰度分析(n = 7, x &#175; &#177; s )</p><p>注：与模型组(C)相比<sup>*</sup>P &lt; 0.05，<sup>**</sup>P &lt; 0.01，<sup>***</sup>P &lt; 0.001，N为空白组；C：模型对照组；R：罗格列酮治疗组(100 mg/kg/d)；High：金芪降糖方高剂量组(500 mg/kg/d)；Low：金芪降糖方低剂量组(250 mg/kg/d)。</p><table-wrap id="table3" ><label><xref ref-type="table" rid="table3">Table 3</xref></label><caption><title> Effects of Jinqi Jiangtang formula and its components on the survival rate of HepG2 cell</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >Groups</th><th align="center" valign="middle" >Dose (&#181;g/ml)</th><th align="center" valign="middle" >Survival (%)</th></tr></thead><tr><td align="center" valign="middle" >N</td><td align="center" valign="middle" >—</td><td align="center" valign="middle" >100 &#177; 2.80</td></tr><tr><td align="center" valign="middle"  rowspan="3"  >AS</td><td align="center" valign="middle" >0.1</td><td align="center" valign="middle" >105.94 &#177; 7.10</td></tr><tr><td align="center" valign="middle" >1</td><td align="center" valign="middle" >102.98 &#177; 4.94</td></tr><tr><td align="center" valign="middle" >10</td><td align="center" valign="middle" >112.54 &#177; 7.02</td></tr><tr><td align="center" valign="middle"  rowspan="3"  >HT</td><td align="center" valign="middle" >0.1</td><td align="center" valign="middle" >114.38 &#177; 9.32</td></tr><tr><td align="center" valign="middle" >1</td><td align="center" valign="middle" >102.16 &#177; 4.31</td></tr><tr><td align="center" valign="middle" >10</td><td align="center" valign="middle" >100.63 &#177; 4.26</td></tr><tr><td align="center" valign="middle"  rowspan="3"  >CA</td><td align="center" valign="middle" >0.1</td><td align="center" valign="middle" >116.18 &#177; 3.65</td></tr><tr><td align="center" valign="middle" >1</td><td align="center" valign="middle" >103.76 &#177; 4.22</td></tr><tr><td align="center" valign="middle" >10</td><td align="center" valign="middle" >106.33 &#177; 4.70</td></tr><tr><td align="center" valign="middle"  rowspan="3"  >JQ</td><td align="center" valign="middle" >0.1</td><td align="center" valign="middle" >101.89 &#177; 5.09</td></tr><tr><td align="center" valign="middle" >1</td><td align="center" valign="middle" >108.34 &#177; 3.56</td></tr><tr><td align="center" valign="middle" >10</td><td align="center" valign="middle" >102.87 &#177; 3.01</td></tr><tr><td align="center" valign="middle"  rowspan="3"  >LA</td><td align="center" valign="middle" >0.1</td><td align="center" valign="middle" >106.13 &#177; 4.06</td></tr><tr><td align="center" valign="middle" >1</td><td align="center" valign="middle" >101.16 &#177; 6.38</td></tr><tr><td align="center" valign="middle" >10</td><td align="center" valign="middle" >101.48 &#177; 4.58</td></tr></tbody></table></table-wrap><p>表3. 金芪降糖方及其组分对HepG2细胞存活率的影响(n = 6, x &#175; &#177; s )</p><p>注：AS为黄芪总皂苷组；HT为黄芪总黄酮组；CA为黄连总生物碱组；JQ为金芪降糖方全方组；LA为金银花总有机酸组。</p></sec><sec id="s7_2_2"><title>3.2.2. 金芪降糖方及各组分对游离脂肪酸诱导HepG2细胞内TG的影响</title><p>如表4所示，各给药组均能降低HepG2细胞内TG蓄积的作用，且各组作用趋势均随着给药浓度的降低而减弱，具有明显的量效关系。</p><table-wrap-group id="4"><label><xref ref-type="table" rid="table4">Table 4</xref></label><caption><title> Effect of each group on TG content in HepG2 cells induced by free fatty aci</title></caption><table-wrap id="4_1"><table><tbody><thead><tr><th align="center" valign="middle" >Groups</th><th align="center" valign="middle" >Dose (μmol/L)</th><th align="center" valign="middle" >TG (mmol/L)</th></tr></thead><tr><td align="center" valign="middle" >N</td><td align="center" valign="middle" >—</td><td align="center" valign="middle" >0.54 &#177; 0.11<sup>***</sup></td></tr><tr><td align="center" valign="middle" >C</td><td align="center" valign="middle" >200</td><td align="center" valign="middle" >5.39 &#177; 0.06</td></tr><tr><td align="center" valign="middle" >Orli</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" >4.09 &#177; 0.16<sup>**</sup></td></tr><tr><td align="center" valign="middle"  rowspan="3"  >AS</td><td align="center" valign="middle" >10</td><td align="center" valign="middle" >1.88 &#177; 0.07<sup>***</sup></td></tr><tr><td align="center" valign="middle" >1</td><td align="center" valign="middle" >3.32 &#177; 0.34<sup>*</sup></td></tr><tr><td align="center" valign="middle" >0.1</td><td align="center" valign="middle" >4.54 &#177; 0.12<sup>*</sup></td></tr><tr><td align="center" valign="middle"  rowspan="3"  >HT</td><td align="center" valign="middle" >10</td><td align="center" valign="middle" >1.95 &#177; 0.07<sup>***</sup></td></tr><tr><td align="center" valign="middle" >1</td><td align="center" valign="middle" >3.14 &#177; 0.35<sup>*</sup></td></tr><tr><td align="center" valign="middle" >0.1</td><td align="center" valign="middle" >4.58 &#177; 0.13<sup>*</sup></td></tr><tr><td align="center" valign="middle"  rowspan="3"  >CA</td><td align="center" valign="middle" >10</td><td align="center" valign="middle" >1.99 &#177; 0.09<sup>***</sup></td></tr><tr><td align="center" valign="middle" >1</td><td align="center" valign="middle" >3.44 &#177; 0.28<sup>*</sup></td></tr><tr><td align="center" valign="middle" >0.1</td><td align="center" valign="middle" >4.51 &#177; 0.14<sup>*</sup></td></tr></tbody></table></table-wrap><table-wrap id="4_2"><table><tbody><thead><tr><th align="center" valign="middle"  rowspan="3"  >JQ</th><th align="center" valign="middle" >10</th><th align="center" valign="middle" >2.07 &#177; 0.18<sup>***</sup></th></tr></thead><tr><td align="center" valign="middle" >1</td><td align="center" valign="middle" >3.49 &#177; 0.30<sup>*</sup></td></tr><tr><td align="center" valign="middle" >0.1</td><td align="center" valign="middle" >4.51 &#177; 0.07<sup>***</sup></td></tr><tr><td align="center" valign="middle"  rowspan="3"  >LA</td><td align="center" valign="middle" >10</td><td align="center" valign="middle" >2.08 &#177; 0.11<sup>***</sup></td></tr><tr><td align="center" valign="middle" >1</td><td align="center" valign="middle" >3.44 &#177; 0.16<sup>***</sup></td></tr><tr><td align="center" valign="middle" >0.1</td><td align="center" valign="middle" >4.52 &#177; 0.12<sup>*</sup></td></tr></tbody></table></table-wrap></table-wrap-group><p>表4. 各组对游离脂肪酸诱导HepG2细胞内TG含量的影响(n = 6, x &#175; &#177; s )</p><p>与模型组相比较，<sup>*</sup>P &lt; 0.05，<sup>**</sup>P &lt; 0.01，<sup>***</sup>P &lt; 0.001。</p><p>注：N为正常对照组；C为模型组；Orli为奥利司他对照组；AS为黄芪总皂苷组；HT为黄芪总黄酮组；CA为黄连总生物碱组；JQ为金芪降糖方全方组；LA为金银花总有机酸组。</p></sec></sec><sec id="s7_3"><title>3.3. 金芪降糖方及其组分抑制HepG2细胞脂质蓄积的研究</title><sec id="s7_3_1"><title>3.3.1. 各靶点抑制剂/激动剂对诱导后HepG2细胞存活率的影响</title><p>如表5所示，各靶点抑制剂/激动剂对HepG2细胞都不具有细胞毒作用。</p><table-wrap id="table5" ><label><xref ref-type="table" rid="table5">Table 5</xref></label><caption><title> The survival rate of HepG2 cells induced by various target inhibitors/agonist</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >Groups</th><th align="center" valign="middle" >Dose (μmol/L)</th><th align="center" valign="middle" >Survival (%)</th></tr></thead><tr><td align="center" valign="middle" >N</td><td align="center" valign="middle" >—</td><td align="center" valign="middle" >100 &#177; 0.01</td></tr><tr><td align="center" valign="middle" >Compound C</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" >105.23 &#177; 2.65</td></tr><tr><td align="center" valign="middle" >IGF-1</td><td align="center" valign="middle" >50 &#181;g/ml</td><td align="center" valign="middle" >106.56 &#177; 1.14</td></tr><tr><td align="center" valign="middle" >STO-609</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" >108.03 &#177; 0.35</td></tr><tr><td align="center" valign="middle" >Cytochalasin B</td><td align="center" valign="middle" >10</td><td align="center" valign="middle" >108.78 &#177; 0.80</td></tr></tbody></table></table-wrap><p>表5. 各靶点抑制剂/激动剂诱导后HepG2细胞的存活率(n = 6, x &#175; &#177; s )</p></sec><sec id="s7_3_2"><title>3.3.2. 金芪降糖方及其组分对HepG2细胞脂质蓄积作用机制的研究</title><p>1) AMPK抑制剂Dorsomorphin (Compound C)对金芪降糖方及其各组分抑制HepG2细胞内TG蓄积的影响。</p><p>如表6所示，与未添加抑制剂组比较，添加抑制剂组(JQ和CA)抑制细胞内TG蓄积的作用被减弱或消除。</p><table-wrap id="table6" ><label><xref ref-type="table" rid="table6">Table 6</xref></label><caption><title> Effect of compound C on inhibiting the level of TG in HepG2 cell</title></caption><table><tbody><thead><tr><th align="center" valign="middle"  rowspan="2"  >分组</th><th align="center" valign="middle"  colspan="2"  >TG (mmol/L)</th></tr></thead><tr><td align="center" valign="middle" >Drug (10 &#181;g/ml)</td><td align="center" valign="middle" >+Compound C (1μmol/L)</td></tr><tr><td align="center" valign="middle" >AS</td><td align="center" valign="middle" >0.48 &#177; 0.06</td><td align="center" valign="middle" >0.58 &#177; 0.04</td></tr><tr><td align="center" valign="middle" >HT</td><td align="center" valign="middle" >0.46 &#177; 0.03</td><td align="center" valign="middle" >0.51 &#177; 0.01</td></tr><tr><td align="center" valign="middle" >CA</td><td align="center" valign="middle" >0.39 &#177; 0.02</td><td align="center" valign="middle" >0.52 &#177; 0.02*</td></tr><tr><td align="center" valign="middle" >JQ</td><td align="center" valign="middle" >0.39 &#177; 0.01</td><td align="center" valign="middle" >0.52 &#177; 0.02**</td></tr><tr><td align="center" valign="middle" >LA</td><td align="center" valign="middle" >0.42 &#177; 0.04</td><td align="center" valign="middle" >0.55 &#177; 0.02</td></tr></tbody></table></table-wrap><p>表6. Compound C对各组抑制HepG2细胞内TG水平的影响(n = 6, x &#175; &#177; s )</p><p>注：添加抑制剂组与药物组(Drug)比较，<sup> *</sup>P &lt; 0.05，<sup>**</sup>P &lt; 0.01，<sup>***</sup>P &lt; 0.001；AS为黄芪总皂苷组；HT为黄芪总黄酮组；CA为黄连总生物碱组；JQ为金芪降糖方全方组；LA为金银花总有机酸组。</p><p>2) CaMKK抑制剂STO-609对金芪降糖方及其各组分抑制HepG2细胞内TG蓄积的影响</p><p>如表7所示，与未添加抑制剂组比较，添加抑制剂组的(AS、HT和JQ)抑制细胞内TG蓄积的作用被减弱或消除。</p><table-wrap id="table7" ><label><xref ref-type="table" rid="table7">Table 7</xref></label><caption><title> Effect of STO-609 on inhibiting the level of TG in HepG2 cell</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >分组</th><th align="center" valign="middle"  colspan="2"  >TG (mmol/L)</th></tr></thead><tr><td align="center" valign="middle" ></td><td align="center" valign="middle" >Drug (10 &#181;g/ml)</td><td align="center" valign="middle" >+ STO-609 (1 μmol/L)</td></tr><tr><td align="center" valign="middle" >AS</td><td align="center" valign="middle" >0.20 &#177; 0.01</td><td align="center" valign="middle" >0.27 &#177; 0.00***</td></tr><tr><td align="center" valign="middle" >HT</td><td align="center" valign="middle" >0.19 &#177; 0.01</td><td align="center" valign="middle" >0.25 &#177; 0.01*</td></tr><tr><td align="center" valign="middle" >CA</td><td align="center" valign="middle" >0.17 &#177; 0.01</td><td align="center" valign="middle" >0.19 &#177; 0.01</td></tr><tr><td align="center" valign="middle" >JQ</td><td align="center" valign="middle" >0.20 &#177; 0.00</td><td align="center" valign="middle" >0.25 &#177; 0.01*</td></tr><tr><td align="center" valign="middle" >LA</td><td align="center" valign="middle" >0.18 &#177; 0.02</td><td align="center" valign="middle" >0.22 &#177; 0.01</td></tr></tbody></table></table-wrap><p>表7. STO-609对各组抑制HepG2细胞内TG水平的影响(n = 6, x &#175; &#177; s )</p><p>注：添加抑制剂组与药物组(Drug)比较，<sup>*</sup>P &lt; 0.05，<sup>**</sup>P &lt; 0.01，<sup>***</sup>P &lt; 0.001；AS为黄芪总皂苷组；HT为黄芪总黄酮组；CA为黄连总生物碱组；JQ为金芪降糖方全方组；LA为金银花总有机酸组。</p><p>3) PI3K激动剂IGF-1对金芪降糖方及其各组分抑制HepG2细胞内TG蓄积的影响</p><p>如表8所示，与未添加抑制剂组比较，添加抑制剂的金芪降糖方及各组分抑制细胞内TG蓄积的作用均被减弱或消除。</p><table-wrap id="table8" ><label><xref ref-type="table" rid="table8">Table 8</xref></label><caption><title> Effect of IGF-1 on inhibiting the level of TG in HepG2 cell</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >分组</th><th align="center" valign="middle"  colspan="2"  >TG (mmol/L)</th></tr></thead><tr><td align="center" valign="middle" ></td><td align="center" valign="middle" >Drug (10 &#181;g/ml)</td><td align="center" valign="middle" >+IGF-1 (50 &#181;g/ml)</td></tr><tr><td align="center" valign="middle" >AS</td><td align="center" valign="middle" >0.15 &#177; 0.01</td><td align="center" valign="middle" >0.22 &#177; 0.01*</td></tr><tr><td align="center" valign="middle" >HT</td><td align="center" valign="middle" >0.13 &#177; 0.01</td><td align="center" valign="middle" >0.21 &#177; 0.01*</td></tr><tr><td align="center" valign="middle" >CA</td><td align="center" valign="middle" >0.17 &#177; 0.01</td><td align="center" valign="middle" >0.22 &#177; 0.00*</td></tr><tr><td align="center" valign="middle" >JQ</td><td align="center" valign="middle" >0.17 &#177; 0.01</td><td align="center" valign="middle" >0.23 &#177; 0.01*</td></tr><tr><td align="center" valign="middle" >LA</td><td align="center" valign="middle" >0.14 &#177; 0.01</td><td align="center" valign="middle" >0.22 &#177; 0.01*</td></tr></tbody></table></table-wrap><p>表8. IGF-1对各组抑制HepG2细胞内TG水平的影响(n = 6, x &#175; &#177; s )</p><p>注：添加抑制剂组内与药物组(Drug)比较，<sup> *</sup>P &lt; 0.05，<sup>**</sup>P &lt; 0.01，<sup>***</sup>P &lt; 0.001；AS为黄芪总皂苷组；HT为黄芪总黄酮组；CA为黄连总生物碱组；JQ为金芪降糖方全方组；LA为金银花总有机酸组。</p><p>4) GLUT4抑制剂Cytochalasin B对金芪降糖方及其各组分抑制HepG2细胞内TG蓄积的影响</p><p>与未添加抑制剂组比较，添加抑制剂的金芪降糖方及各组分抑制细胞内TG蓄积的作用均被减弱或消除，如表9。</p><table-wrap-group id="9"><label><xref ref-type="table" rid="table9">Table 9</xref></label><caption><title> Effect of cytochalasin B on inhibiting the level of TG in HepG2 cell</title></caption><table-wrap id="9_1"><table><tbody><thead><tr><th align="center" valign="middle" >分组</th><th align="center" valign="middle"  colspan="2"  >TG (mmol/L)</th></tr></thead><tr><td align="center" valign="middle" ></td><td align="center" valign="middle" >Drug (10 &#181;g/ml)</td><td align="center" valign="middle" >+Glut4 (10 μmol/L)</td></tr><tr><td align="center" valign="middle" >AS</td><td align="center" valign="middle" >0.31 &#177; 0.02</td><td align="center" valign="middle" >0.51 &#177; 0.03*</td></tr><tr><td align="center" valign="middle" >HT</td><td align="center" valign="middle" >0.22 &#177; 0.03</td><td align="center" valign="middle" >0.51 &#177; 0.05*</td></tr></tbody></table></table-wrap><table-wrap id="9_2"><table><tbody><thead><tr><th align="center" valign="middle" >CA</th><th align="center" valign="middle" >0.39 &#177; 0.01</th><th align="center" valign="middle" >0.54 &#177; 0.01***</th></tr></thead><tr><td align="center" valign="middle" >JQ</td><td align="center" valign="middle" >0.39 &#177; 0.02</td><td align="center" valign="middle" >0.52 &#177; 0.02*</td></tr><tr><td align="center" valign="middle" >LA</td><td align="center" valign="middle" >0.37 &#177; 0.01</td><td align="center" valign="middle" >0.47 &#177; 0.02*</td></tr></tbody></table></table-wrap></table-wrap-group><p>表9. Cytochalasin B对各组抑制HepG2细胞内TG水平的影响(n = 6, x &#175; &#177; s )</p><p>注：添加抑制剂组内与药物组(Drug)比较，<sup> *</sup>P &lt; 0.05，<sup>**</sup>P &lt; 0.01，<sup>***</sup>P &lt; 0.001；AS为黄芪总皂苷组；HT为黄芪总黄酮组；CA为黄连总生物碱组；JQ为金芪降糖方全方组；LA为金银花总有机酸组。</p></sec></sec></sec><sec id="s8"><title>4. 讨论</title><sec id="s8_1"><title>4.1. “脾主为卫”功能正常是糖脂代谢平衡的重要前提</title><p>脾运化水谷精微，充养卫气，行使卫外防御功能，即“脾为之卫”理论。该理论最早可追溯至《灵枢&#183;五癃津液别》“五脏六腑，心为之主……脾为之卫，肾为之主外”的论述，《灵枢&#183;师传》亦见“脾者主为卫”记载。“脾”护卫功能的临床意义在于 [<xref ref-type="bibr" rid="hanspub.42506-ref8">8</xref>]：未病护脾可防发病，已病健脾可促病愈，病愈补脾可防复发。现代医家对其理解为：脾脏对于致病因素有主导防御作用，且在此基础上还可协同他脏发挥祛邪抑病、维持内环境稳态的功能 [<xref ref-type="bibr" rid="hanspub.42506-ref5">5</xref>]。</p><p>中医精微物质转化与西医糖脂能量代谢存在着高度一致性 [<xref ref-type="bibr" rid="hanspub.42506-ref9">9</xref>]。糖、脂是精微物质的主要构成成分，“脾主为卫”功能正常是可能糖脂代谢平衡的重要前提 [<xref ref-type="bibr" rid="hanspub.42506-ref10">10</xref>]。正如李东垣所云：“脾受胃禀，乃能熏熟五谷”，脾病则运化无力，水谷精微堆积，壅滞日久的“湿浊、痰浊、血瘀”成为糖脂代谢病的“病原”和“病理”，故从中医理论出发，将糖脂代谢病命名为“瘅浊” [<xref ref-type="bibr" rid="hanspub.42506-ref11">11</xref>]，由“瘅”致“浊”、相互交织、相互促进，与后期血管病变、多器官及系统损害的病理过程和临床表现具有一致性 [<xref ref-type="bibr" rid="hanspub.42506-ref12">12</xref>]。</p></sec><sec id="s8_2"><title>4.2. 内环境稳态失衡是“脾主为卫”糖脂代谢紊乱的关键环节</title><p>中医所指的“阴平阳秘”与西医所言“内环境稳态”均是通过相似的机体自身调节机制实现的 [<xref ref-type="bibr" rid="hanspub.42506-ref13">13</xref>]。前者通过多成分、多靶点、多环节发挥作用，同步干预疾病发生发展的多个病理节点，逐步恢复机体内稳态，达到“治本”的作用，后者通过内环境系统内各通路间的平衡协调反馈控制完成。内环境稳态失衡则糖脂代谢出现紊乱，与中医“脾虚”失去了运化功能，水谷精微输布障碍的理论相符合，故“脾主为卫”环节在保证糖脂代谢稳态过程中起着至关重要的作用。</p><p>中药通过同时干预多条通路以调节疾病状态下失衡的代谢网络发挥整体疗效 [<xref ref-type="bibr" rid="hanspub.42506-ref14">14</xref>]。虽然每条信号通路都有自身的路径引起激活状态，但是不同通路之间往往又会产生交互作用和影响，这或许就是“脾主为卫”环节通过多通路多靶点改善糖脂代谢紊乱的基础和综合疗效所在。在本实验中，金芪降糖方明显上调KKA<sup>y</sup>小鼠骨骼肌内PI3K、p-PI3K、AKT、p-AKT蛋白的表达，且不同程度地作用于AMPK及上游的各个靶点。实验结果表明，金芪降糖方具有多组分(益气–活血–化痰)、多层次(气–血–津液)、多途径(血管–脾脏–肌肉)作用特点，可同时激活AMPK和PI3k/Akt途径，活化的AMPK和AKT促进并加强GLUT4转位，加快葡萄糖利用，进而对细胞中的脂肪蓄积起到抑制作用，从而系统揭示了“脾主为卫”环节改善糖脂代谢紊乱的科学内涵。</p><p>在坚持辨证论治的基础上，“脾主为卫”失常与糖脂代谢病的病变特点是相吻合的。通过对其拓展运用，可更全面、准确地解释现代研究发现的 [<xref ref-type="bibr" rid="hanspub.42506-ref15">15</xref>] [<xref ref-type="bibr" rid="hanspub.42506-ref16">16</xref>] 益气活血法可以对脂肪蓄积起到抑制作用的中医内涵，真正意义上实践“不治已病治未病”的思想，为深入理解机体代谢内稳态及其调控机制提供了重要支撑。</p></sec></sec><sec id="s9"><title>文章引用</title><p>李 莉,王 涛. 探索“脾主为卫”环节对糖脂代谢稳态的调节机制Explore Regulation Mechanism of “The Spleen for Defend” on Homeostasis of Glucose and Fat Metabolism[J]. 中医学, 2021, 10(03): 343-251. https://doi.org/10.12677/TCM.2021.103048</p></sec><sec id="s10"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.42506-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Kokubo, Y. (2011) Associations of Impaired Glucose Metabolism and Dyslipidemia with Cardiovascular Diseases: What Have We Learned from Japanese Cohort Studies for Individualized Prevention and Treatment? EPMA Journal, 2, 75-81. &lt;br&gt;https://doi.org/10.1007/s13167-011-0074-1</mixed-citation></ref><ref id="hanspub.42506-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Sasaki, J., Otonari, T., Uchida, Y., et al. (2013) Effects of Pravastatin and Atorvastatin on HDL Cholesterol and Glucose Metabolism in Patients with Dyslipidemia and Glucose Intolerance: The PRAT Study. Journal of Atherosclerosis &amp; Thrombosis, 20, 368-379. &lt;br&gt;https://doi.org/10.5551/jat.13532</mixed-citation></ref><ref id="hanspub.42506-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">中国成人血脂异常防治指南修订联合委员会. 中国成人血脂异常防治指南(2016年修订版) [J]. 中国循环杂志, 2016, 31(10): 937-950.</mixed-citation></ref><ref id="hanspub.42506-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">郭姣, 肖雪, 荣向路, 等. 糖脂代谢病与精准医学[J]. 世界科学技术–中医药现代化, 2017, 19(1): 50-54.</mixed-citation></ref><ref id="hanspub.42506-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">王珍, 刘友章, 王秀丽. “脾为之卫”理论浅探[J]. 新中医, 2011, 43(3): 5-7.</mixed-citation></ref><ref id="hanspub.42506-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">袁卫玲, 苏玮莲, 马佐英, 等. 论中医脾功能变化与糖脂代谢关系[J]. 中国中医药信息杂志, 2015, 22(10): 7-8.</mixed-citation></ref><ref id="hanspub.42506-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">李晔, 李秋贵. 金芪降糖片治疗2型糖尿病临床经验[J]. 中国中医药现代远程教育, 2005, 3(6): 49-50.</mixed-citation></ref><ref id="hanspub.42506-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">汪运富. 论“脾主为卫”[J]. 山东中医药大学学报, 2001, 25(3): 209-214.</mixed-citation></ref><ref id="hanspub.42506-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">李柳梅, 纪云西. 中医“气衰气少”与糖脂物质能量转化[J]. 中华中医药学刊, 2017, 35(11): 2865-2867.</mixed-citation></ref><ref id="hanspub.42506-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">杨宇峰, 刘军彤. 脾气虚证代谢综合征大鼠血清脂质代谢生物标志物代谢组学研究[J]. 中医药导报, 2020, 26(6): 19-22.</mixed-citation></ref><ref id="hanspub.42506-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">世界中医药学会联合会代谢病专业委员会. 糖脂代谢病(瘅浊)中西医结合诊疗技术规范[S]. 北京: 中国医药科技出版社, 2019.</mixed-citation></ref><ref id="hanspub.42506-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">李敏谦, 林育, 项磊, 等. 瘅浊与糖脂代谢病[J]. 世界中医药, 2019, 14(3): 652-655.</mixed-citation></ref><ref id="hanspub.42506-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">黄建华, 卞琴, 李文伟, 等. 稳态作为中医“证”研究的新思路的依据和意义[J]. 中国中西医结合杂志, 2012, 32(1): 111-114.</mixed-citation></ref><ref id="hanspub.42506-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">林玉芳, 韩薇, 李寅, 等. 中医药对胰岛素抵抗相关信号通路影响的研究进展[J]. 上海中医药大学学报, 2015, 29(5): 98-101.</mixed-citation></ref><ref id="hanspub.42506-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">刘桠, 康健, 高泓. 从“脾胰同源”论血糖波动的中医辨治思路[J]. 辽宁中医杂志, 2015, 42(7): 1246-1247.</mixed-citation></ref><ref id="hanspub.42506-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">刘望舒, 陈筱云. 2型糖尿病胰岛素抵抗与脾的关系探析[J]. 山西中医学院学报, 2016, 17(1): 75-76.</mixed-citation></ref></ref-list></back></article>